TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$39.53
0.22 (0.56%)
▲
5d:
+0.87%
30d:
+5.44%
90d:
+12.01%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 03, 2026
30d
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: TEVA shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: TEVA shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$66.06
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$41.02
3.6% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $39.53, which is considered extended relative to its 30-day fair value range of $36.84 to $39.48. From a valuation perspective, the stock is trading at a premium (Forward PE: 12.8) compared to its historical average (11.0). At these levels, the market is pricing in 5.1% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TEVA is in a strong uptrend. Immediate support is located at $38.30, while resistance sits at $40.79.
Market Sentiment: TEVA scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $46.29 (+17.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TEVA is in a strong uptrend. Immediate support is located at $38.30, while resistance sits at $40.79.
Market Sentiment: TEVA scores 31/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $46.29 (+17.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$36.84 -
$39.48
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
25.2%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (31/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($46.29)
- NEUTRAL: Trading at premium valuation - market expects 5.1% growth which is achievable
- WARNING: Composite score 44/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$36.84 -
$39.48
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$38.30
Resistance Level
$40.79
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.82
Wall Street Target
$46.29
(+17.1%)
Revenue Growth (YoY)
-0.8%
Earnings Growth (YoY)
72.2%
Profit Margin
4.1%
Valuation Premium vs History
+5.1% premium
PE vs Historical
12.8 vs 11.0
STRETCHED
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+5.1%
(market-implied from PE analysis)
1-Year Target
$41.55
(+5%)
2-Year Target
$43.66
(+11%)
3-Year Target
$45.89
(+16%)
3-Yr Target (if PE normalizes)
(PE: 13→11)
PE COMPRESSION
$39.38
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.4, Growth: 42.2%)
$181.00
(+358%)
Base:
(SPY PE: 12.8, Growth: 42.2%)
$113.72
(+188%)
Bear:
(PE: 10.9, Growth: 42.2%)
$96.67
(+145%)
📈
Valuation based on Current Earnings
Forward PE: 7.05 | Forward EPS (Implied): $5.61
Bull Case
$47.73
(+21%)
Analyst growth 15.0%, PE expands to 7.4
Base Case
$39.53
(0%)
Market implied 0.0%, PE stable at 7.1
Bear Case
$30.24
(-24%)
Severe decline -15.0%, PE contracts to 6.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: October 03, 2026 6:33 PM ET
Data refreshes hourly during market hours. Next update: 7:33 PM
Data refreshes hourly during market hours. Next update: 7:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
